Want to see DCGO full AI Analyst Report?
Top Page
DocGo
(NASDAQ:DCGO)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.28
▼(-26.58% Downside)
Action:Reiterated
Date:10/20/26
The score is held down primarily by weak financial performance (recent losses, declining revenue, and TTM free-cash-flow burn) and bearish technicals (price below key moving averages with negative MACD). The earnings call provides partial support via improved revenue outlook, record volumes, and cost/AI initiatives, but widened loss guidance, declining liquidity, and acquisition-related uncertainty keep overall risk elevated.
Positive Factors
Broad Volume Growth
Record volume growth across transportation, home care, phlebotomy, monitoring and virtual care indicates broad demand rather than dependence on one service. This supports platform utilization, customer relevance and potential operating leverage as the company scales.
Negative Factors
Profitability Deterioration
The shift from modest profitability to deep operating and net losses, alongside declining revenue, shows that current cost levels are overwhelming gross profit. Persistent losses could restrict reinvestment, weaken returns and increase reliance on external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Broad Volume Growth
Record volume growth across transportation, home care, phlebotomy, monitoring and virtual care indicates broad demand rather than dependence on one service. This supports platform utilization, customer relevance and potential operating leverage as the company scales.
Read all positive factors
DocGo (DCGO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$28.24M
Dividend YieldN/A
Average Volume (3M)588.66K
Price to Earnings (P/E)―
Beta (1Y)1.73
Revenue Growth-32.40%
EPS Growth-969.05%
CountryUS
Employees3,568
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-1.96
Shares Outstanding98,992,350
10 Day Avg. Volume557,414
30 Day Avg. Volume588,659
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.60
Price to Sales (P/S)0.27
P/FCF Ratio3.22
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue0.10
Enterprise Value/Gross Profit0.32
Enterprise Value/Ebitda-0.18
Forecast
1Y Price Target
$2.17Price Target Upside470.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$306.63M
DocGo Business Overview & Revenue Model
Company Description
DocGo Inc. is a company dedicated to providing mobile healthcare solutions and medical transportation for a wide array of healthcare organizations in both the United States and the United Kingdom. Their transportation portfolio includes critical e...
DocGo Earnings Call Summary
Earnings Call Date:Aug 17, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 09, 2026
Earnings Call Sentiment Neutral
The call conveyed strong operational momentum (record volumes across multiple business lines, solid organic growth after excluding one-time migrant revenues, a strategic acquisition with committed financing, and tangible AI-driven efficiency programs) alongside material near-term financial pressures (widened adjusted EBITDA loss guidance, ongoing negative adjusted EBITDA, declining cash balances, margin compression in mobile health, and the addition of assumed Hicuity debt). Management expects improvements (positive adjusted EBITDA run rate exiting 2026) but execution and timing risks remain.Positive Updates
Strategic Acquisition — Hicuity Health
Signed definitive agreement to acquire Hicuity Health (trailing 12-month revenue ~$65M; adjusted EBITDA ~$4.5M). Transaction includes assumption of existing Hicuity debt (~$52M maturing Dec 2029), equity consideration of 2% of DocGo fully diluted common stock at closing, and potential additional 3.5% if market cap reaches $250M within three years. Perceptive Advisors committed up to $50M in financing (first tranche $12.5M tied to a services agreement).
Negative Updates
Quarterly Revenue Decline and Migrant Wind-Down
Total Q2 revenue declined to $73.4M from $80.4M YoY; decline was driven by the wind-down of migrant-related projects which materially reduced mobile health revenue (mobile health revenue down to $21.4M from $30.8M).
Read all updates
Q2-2026 Updates
Positive
Negative
Strategic Acquisition — Hicuity Health
Signed definitive agreement to acquire Hicuity Health (trailing 12-month revenue ~$65M; adjusted EBITDA ~$4.5M). Transaction includes assumption of existing Hicuity debt (~$52M maturing Dec 2029), equity consideration of 2% of DocGo fully diluted common stock at closing, and potential additional 3.5% if market cap reaches $250M within three years. Perceptive Advisors committed up to $50M in financing (first tranche $12.5M tied to a services agreement).
Read all positive updates
Company Guidance
DocGo narrowed full‑year revenue guidance to $305–$310 million (up from prior ranges and excluding any Hicuity contribution and migrant‑related revenues), which management says would represent roughly 21%–23% growth over 2025 base revenues; at the same time full‑year adjusted EBITDA loss guidance was widened to a loss of $17–$22 million (vs. prior guidance of a $5–$10 million loss) after a larger‑than‑anticipated H1 (Q1 adj. EBITDA loss $10.3M; Q2 loss $6.3M, a ~40% sequential improvement versus Q1), though the company expects to reach a positive adjusted EBITDA run‑rate exiting 2026 and be positioned for a strong 2027. Management cited expected cost savings of about $6 million annually from efficiency initiatives (10 active programs now, ~20 more launching late 2026/early 2027), AI efficiencies that already handle 60% of inbound phlebotomy calls and 100% of outbound scheduling with data‑entry integrations at 65% (target 90% by year‑end) and per‑order processing costs falling from $2 to pennies; guidance does not assume Hicuity (Hicuity TTM revenue ~$65M and adjusted EBITDA ~$4.5M; assumed debt ~$52M maturing Dec‑2029) and will be updated as closing timing and Perceptive’s financing (up to $50M committed, first $12.5M tranche) become clear; balance sheet at June 30 showed $48.1M cash ($25.2M available).DocGo Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
60
Neutral
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 294.72M | 322.20M | 616.56M | 624.29M | 440.52M | 318.72M |
| Gross Profit | 88.78M | 98.76M | 213.57M | 195.38M | 154.72M | 109.75M |
| EBITDA | -158.09M | -170.82M | 45.56M | 32.73M | 33.35M | 27.63M |
| Net Income | -192.42M | -182.40M | 19.99M | 6.86M | 34.58M | 23.74M |
Balance Sheet | ||||||
| Total Assets | 186.82M | 217.10M | 455.62M | 490.45M | 393.28M | 309.60M |
| Cash, Cash Equivalents and Short-Term Investments | 25.23M | 51.02M | 89.24M | 59.29M | 157.34M | 175.54M |
| Total Debt | 25.91M | 29.18M | 57.19M | 46.50M | 19.91M | 16.51M |
| Total Liabilities | 91.04M | 91.23M | 140.44M | 185.28M | 114.35M | 82.55M |
| Stockholders Equity | 119.05M | 144.01M | 320.92M | 300.79M | 273.23M | 219.58M |
Cash Flow | ||||||
| Free Cash Flow | -27.14M | 27.02M | 64.50M | -74.35M | 23.37M | -8.60M |
| Operating Cash Flow | -22.71M | 34.45M | 70.34M | -64.22M | 28.87M | -1.95M |
| Investing Cash Flow | -14.19M | -39.08M | -10.87M | -29.88M | -38.45M | -8.59M |
| Financing Cash Flow | -39.04M | -50.82M | -24.15M | 1.12M | -6.18M | 155.21M |
DocGo Technical Analysis
Negative
0.38
Price Trends
0.36
Negative
0.48
Negative
0.58
Negative
Market Momentum
-0.03
Negative
36.24
Neutral
36.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DCGO, the sentiment is Negative. The current price of 0.38 is above the 20-day moving average (MA) of 0.32, above the 50-day MA of 0.36, and below the 200-day MA of 0.58, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 36.24 is Neutral, neither overbought nor oversold. The STOCH value of 36.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DCGO.
DocGo Risk Analysis
DocGo disclosed 72 risk factors in its most recent earnings report. DocGo reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
DocGo Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | $2.26B | 21.33 | 9.57% | ― | 15.88% | 25.01% | |
70 Outperform | $2.88B | 9.93 | 150.20% | ― | 19.52% | 1337.90% | |
67 Neutral | $370.60M | 25.80 | 10.30% | ― | 25.21% | 6.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $28.24M | -0.15 | -115.58% | ― | -32.40% | -969.05% | |
38 Underperform | $1.10M | -0.02 | -46.21% | ― | -35.26% | 51.06% |
* Healthcare Sector Average
DCGO
DocGo
0.29
-0.86
-75.00%
ADUS
Addus Homecare
121.17
-0.29
-0.24%
VMD
Viemed Healthcare
9.73
2.78
40.00%
AVAH
Aveanna Healthcare Holdings
13.18
3.55
36.86%
EUDA
EUDA Health Holdings
14.46
-29.54
-67.14%
MNDR
Mobile-health Network Solutions Class A
0.93
-16.42
-94.67%
DocGo Corporate Events
Business Operations and StrategyPrivate Placements and Financing
DocGo Secures New Credit Facility and Warrant Financing
Neutral
Oct 5, 2026
On October 1, 2026, DocGo and subsidiaries Hicuity and Ambulnz entered into an amended and restated credit agreement and guaranty that refinances existing debt and adds new term loan facilities totaling up to $102 million, maturing on December 6, ...
Business Operations and StrategyFinancial DisclosuresM&A TransactionsPrivate Placements and Financing
DocGo to Acquire Hicuity Health, Expanding Virtual Care
Neutral
Aug 17, 2026
DocGo reported second quarter 2026 results on August 17, 2026, posting revenue of $73.4 million versus $80.4 million a year earlier, with the decline entirely tied to the wind-down of migrant-related programs that had contributed $18.8 million in ...
Delistings and Listing ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split
DocGo Granted Nasdaq Extension to Regain Listing Compliance
Neutral
Jul 31, 2026
On July 28, 2026, DocGo Inc. disclosed that it received a determination from Nasdaq granting the company an additional 180 days, until January 25, 2027, to regain compliance with the exchange’s $1.00 minimum bid price requirement for its com...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.